{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:06:19Z","timestamp":1790885179227,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,11,16]],"date-time":"2017-11-16T00:00:00Z","timestamp":1510790400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1038\/leu.2017.331","type":"journal-article","created":{"date-parts":[[2018,1,5]],"date-time":"2018-01-05T15:21:10Z","timestamp":1515165670000},"page":"986-995","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":85,"title":["Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time"],"prefix":"10.1038","volume":"32","author":[{"given":"S K","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Dispenzieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Mingwei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Akpek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Cornell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Freytes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Hashmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Hildebrandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Holmberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Kyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Mikhael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2621-7924","authenticated-orcid":false,"given":"T","family":"Nishihori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Tay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Vesole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Vij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Wirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Gasparetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Mark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Hari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"D'Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,16]]},"reference":[{"key":"BFleu2017331_CR1","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/978-3-319-40320-5_9","volume":"169","author":"J Laubach","year":"2016","unstructured":"Laubach J, Kumar S . Management of transplant-eligible patients with newly diagnosed multiple myeloma. Cancer Treat Res 2016; 169: 145\u2013167.","journal-title":"Cancer Treat Res"},{"key":"BFleu2017331_CR2","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/j.bbmt.2013.08.002","volume":"19","author":"LJ Costa","year":"2013","unstructured":"Costa LJ, Zhang M-J, Zhong X, Dispenzieri A, Lonial S, Krishnan A et al. Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. Biol Blood Marrow Transplant 2013; 19: 1615\u20131624.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFleu2017331_CR3","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med 2017; 376: 1311\u20131320.","journal-title":"N Engl J Med"},{"key":"BFleu2017331_CR4","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1056\/NEJMoa1402888","volume":"371","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 2014; 371: 895\u2013905.","journal-title":"N Engl J Med"},{"key":"BFleu2017331_CR5","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.bbmt.2012.11.002","volume":"19","author":"PN Hari","year":"2013","unstructured":"Hari PN, McCarthy PL . Multiple myeloma: future directions in autologous transplantation and novel agents. Biol Blood Marrow Transplant 2013; 19: S20\u2013S25.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFleu2017331_CR6","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1056\/NEJMe1700453","volume":"376","author":"CA Schiffer","year":"2017","unstructured":"Schiffer CA, Zonder JA . Transplantation for myeloma\u2014now or later? N Engl J Med 2017; 376: 1378\u20131379.","journal-title":"N Engl J Med"},{"key":"BFleu2017331_CR7","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014; 28: 1122\u20131128.","journal-title":"Leukemia"},{"key":"BFleu2017331_CR8","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1038\/leu.2017.185","volume":"31","author":"A D'Souza","year":"2017","unstructured":"D'Souza A, Zhang MJ, Huang J, Fei M, Pasquini M, Hamadani M et al. Trends in pre- and post-transplant therapies with first autologous hematopoietic cell transplantation among patients with multiple myeloma in the United States, 2004-2014. Leukemia 2017; 31: 1998\u20132000.","journal-title":"Leukemia"},{"key":"BFleu2017331_CR9","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/bmt.2014.237","volume":"50","author":"VH Jimenez-Zepeda","year":"2015","unstructured":"Jimenez-Zepeda VH, Reece DE, Trudel S, Chen C, Tiedemann R, Kukreti V . Early relapse after single auto-SCT for multiple myeloma is a major predictor of survival in the era of novel agents. Bone Marrow Transplant 2015; 50: 204\u2013208.","journal-title":"Bone Marrow Transplant"},{"key":"BFleu2017331_CR10","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1038\/leu.2016.147","volume":"30","author":"N Majithia","year":"2016","unstructured":"Majithia N, Rajkumar SV, Lacy MQ, Buadi FK, Dispenzieri A, Gertz MA et al. Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents. Leukemia 2016; 30: 2208\u20132213.","journal-title":"Leukemia"},{"key":"BFleu2017331_CR11","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/cncr.22855","volume":"110","author":"A Palumbo","year":"2007","unstructured":"Palumbo A, Bringhen S, Falco P, Cavallo F, Ambrosini MT, Avonto I et al. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy. Cancer 2007; 110: 824\u2013829.","journal-title":"Cancer"},{"key":"BFleu2017331_CR12","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/bmt.2008.180","volume":"42","author":"S Kumar","year":"2008","unstructured":"Kumar S, Mahmood ST, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK et al. Impact of early relapse after auto-SCT for multiple myeloma. Bone Marrow Transplant 2008; 42: 413\u2013420.","journal-title":"Bone Marrow Transplant"},{"key":"BFleu2017331_CR13","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.bbmt.2013.01.004","volume":"19","author":"LC Michaelis","year":"2013","unstructured":"Michaelis LC, Saad A, Zhong X, Le-Rademacher J, Freytes CO, Marks DI et al. Salvage second hematopoietic cell transplantation in myeloma. Biol Blood Marrow Transplant 2013; 19: 760\u2013766.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFleu2017331_CR14","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467\u20131473.","journal-title":"Leukemia"},{"key":"BFleu2017331_CR15","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1182\/asheducation-2016.1.485","volume":"2016","author":"A Dispenzieri","year":"2016","unstructured":"Dispenzieri A . Myeloma: management of the newly diagnosed high-risk patient. Hematology Am Soc Hematol Educ Program 2016; 2016: 485\u2013494.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"BFleu2017331_CR16","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1182\/blood-2015-05-644039","volume":"126","author":"R Kuiper","year":"2015","unstructured":"Kuiper R, van Duin M, van Vliet MH, Broijl A, van der Holt B, El Jarari L et al. Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System. Blood 2015; 126: 1996\u20132004.","journal-title":"Blood"},{"key":"BFleu2017331_CR17","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1182\/blood-2015-06-653261","volume":"126","author":"S Lonial","year":"2015","unstructured":"Lonial S, Boise LH, Kaufman J . How I treat high-risk myeloma. Blood 2015; 126: 1536\u20131543.","journal-title":"Blood"},{"key":"BFleu2017331_CR18","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1016\/j.bbmt.2016.07.007","volume":"22","author":"EC Scott","year":"2016","unstructured":"Scott EC, Hari P, Sharma M, Le-Rademacher J, Huang J, Vogl D et al. Post-transplant outcomes in high-risk compared with non-high-risk multiple myeloma: a CIBMTR analysis. Biol Blood Marrow Transplant 2016; 22: 1893\u20131899.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFleu2017331_CR19","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","volume":"127","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood 2016; 127: 2955\u20132962.","journal-title":"Blood"},{"key":"BFleu2017331_CR20","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L et al. Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol 2015; 33: 2863\u20132869.","journal-title":"J Clin Oncol"},{"key":"BFleu2017331_CR21","first-page":"719","volume":"14","author":"PM Voorhees","year":"2016","unstructured":"Voorhees PM, Usmani SZ . The role of high-dose melphalan and autologous stem cell transplant in the rapidly evolving era of modern multiple myeloma therapy. Clin Adv Hematol Oncol 2016; 14: 719\u2013728.","journal-title":"Clin Adv Hematol Oncol"},{"key":"BFleu2017331_CR22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1586\/17474086.2014.878645","volume":"7","author":"PL McCarthy","year":"2014","unstructured":"McCarthy PL, Einsele H, Attal M, Giralt S . The emerging role of consolidation and maintenance therapy for transplant-eligible multiple myeloma patients. Exp Rev Hematol 2014; 7: 55\u201366.","journal-title":"Exp Rev Hematol"},{"key":"BFleu2017331_CR23","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1200\/EDBK_159016","volume":"35","author":"A Krishnan","year":"2016","unstructured":"Krishnan A, Vij R, Keller J, Dhakal B, Hari P . Moving beyond autologous transplantation in multiple myeloma: consolidation, maintenance, allogeneic transplant, and immune therapy. Am Soc Clin Oncol Educ Book 2016; 35: 210\u2013221.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"BFleu2017331_CR24","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1038\/bmt.2015.83","volume":"50","author":"M Mohty","year":"2015","unstructured":"Mohty M, Richardson PG, McCarthy PL, Attal M . Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand? Bone Marrow Transplantation 2015; 50: 1024\u20131029.","journal-title":"Bone Marrow Transplantation"},{"key":"BFleu2017331_CR25","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1200\/JCO.2013.54.8164","volume":"32","author":"M Roussel","year":"2014","unstructured":"Roussel M, Lauwers-Cances V, Robillard N, Hulin C, Leleu X, Benboubker L et al. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myelome. J Clin Oncol 2014; 32: 2712\u20132717.","journal-title":"J Clin Oncol"},{"key":"BFleu2017331_CR26","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/leu.2013.335","volume":"28","author":"AK Nooka","year":"2014","unstructured":"Nooka AK, Kaufman JL, Muppidi S, Langston A, Heffner LT, Gleason C et al. Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients. Leukemia 2014; 28: 690\u2013693.","journal-title":"Leukemia"},{"key":"BFleu2017331_CR27","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","volume":"30","author":"P Sonneveld","year":"2012","unstructured":"Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/ GMMG-HD4 trial. J Clin Oncol 2012; 30: 2946\u20132955.","journal-title":"J Clin Oncol"},{"key":"BFleu2017331_CR28","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","volume":"366","author":"M Attal","year":"2012","unstructured":"Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366: 1782\u20131791.","journal-title":"N Engl J Med"},{"key":"BFleu2017331_CR29","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","volume":"366","author":"PL McCarthy","year":"2012","unstructured":"McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366: 1770\u20131781.","journal-title":"N Engl J Med"},{"key":"BFleu2017331_CR30","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","volume":"389","author":"BG Durie","year":"2017","unstructured":"Durie BG, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 2017; 389: 519\u2013527.","journal-title":"Lancet"},{"key":"BFleu2017331_CR31","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","volume":"88","author":"JR Mikhael","year":"2013","unstructured":"Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013. Mayo Clin Proc 2013; 88: 360\u2013376.","journal-title":"Mayo Clin Proc"},{"key":"BFleu2017331_CR32","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa032290","volume":"349","author":"M Attal","year":"2003","unstructured":"Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495\u20132502.","journal-title":"N Engl J Med"},{"key":"BFleu2017331_CR33","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","volume":"35","author":"PL McCarthy","year":"2017","unstructured":"McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol 2017; 35: 3279\u20133289.","journal-title":"J Clin Oncol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/leu2017331.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu2017331","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/leu.2017.331","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/leu2017331.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T18:11:05Z","timestamp":1684433465000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2017331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,16]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["BFleu2017331"],"URL":"https:\/\/doi.org\/10.1038\/leu.2017.331","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,16]]},"assertion":[{"value":"23 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}